---
title: "HR for cancer mortality from weighted models"
subtitle: "GM-UAW Cohort Study"
date: \today
aspectratio: 169
# fontsize: 10pt
output:
  beamer_presentation:
    # latex_engine: lualatex
    includes:
      in_header: "~/HeadRs/BeamerHead.sty"
  # pdf_document:
  #   # latex_engine: lualatex
  #   includes:
  #     in_header: "~/HeadRs/StatHead.sty"
  keep_tex: true
---

```{r setup, include=F}
knitr::opts_chunk$set(echo = F,
											warning = F,
											message = F,
											cache = F,
											fig.align = "center",
											fig.pos = "H",
											results = "asis")

library(here); library(tidyverse); library(data.table);
library(lubridate); library(xtable)

source("~/HeadRs/00-my-theme.R")

```

# Four analyses

\linespread{1.25}

1. Usual mortality models (FU over 1941--1999)
1. Restricted to those still alive in 1985 (FU over 1985--1999)
1. Restricted to those still alive in 1985, weighted by probability of not dying of natural causes (FU over 1985--1999)
1. Restricted to those still alive in 1985, weighted by stabilized inverse probability with truncation at the 99^th^ percentile of weights (FU over 1985--1999)


# Stabilized weight

\linespread{1.25}

$$sw_i = \frac{1 - \bar p}{1 - \hat p_i}$$
where $\hat p_i$ is the $i$^th^ individual's predicted probability of surviving to year 1985, and $\bar p$ is the overall survival proportion i.e. $\frac{1}{n}\sum^n_i\hat p_i$.

<!-- # Age at cohort entry -->

<!-- \begin{center} -->
<!-- \includegraphics[width=\linewidth]{`r here::here("reports/mortality sanity check/resources", "age-at-entry.pdf")`} -->
<!-- \end{center} -->

# Cox PH Models

\linespread{1.25}

- Outcomes: Lung cancer, stomach cancer, prostate cancer, and non-Hodgkin lymphoma
- Cumulative exposure to straight, soluble, and synthetic MWFs (lagged 21, 10, and 5 years)
- Covariates
	- Categorical calendar year
	- Categorical year of hire
	- Race
	- Sex (when possible)
	- Plant
- Risk sets indexed by age

# 

## Lung cancer (straight MWF, FU through 1999)

\begin{table}\linespread{1.15}
\begin{adjustbox}{scale = 0.7}
%\caption{Adjusted HR estimates for lung cancer.}
\begin{tabular}{llrlllrllllllll}
  \toprule & & \multicolumn{3}{c}{Full follow-up}& & \multicolumn{3}{c}{1985 cohort}& & \multicolumn{2}{c}{Weighted by surv.}& & \multicolumn{2}{c}{St. inverse weight}\\
\cline{3-5} \cline{7-9} \cline{11-12} \cline{14-15}
\vspace{0em} & \vspace{0em} & $n$ & HR & 95\% CI &   & $n$ & HR & 95\% CI &   & HR & 95\% CI &   & HR & 95\% CI \\ 
  \midrule
\multicolumn{3}{l}{Lag 21}\\
 & $0$ & 648 &  &  &  & 360 &  &  &  &  &  &  &  &  \\ 
   & $>0$ to $2$  & 333 & 0.94 & (0.79, 1.11) &  & 222 & 0.79 & (0.64, 0.98) &  & 0.77 & (0.62, 0.95) &  & 0.78 & (0.63, 0.97) \\ 
   & $>2$ & 150 & 0.96 & (0.79, 1.17) &  & 112 & 0.86 & (0.68, 1.09) &  & 0.85 & (0.67, 1.09) &  & 0.85 & (0.67, 1.08) \\ 
  \multicolumn{3}{l}{Lag 10}\\
   & $0$ & 507 &  &  &  & 301 &  &  &  &  &  &  &  &  \\ 
   & $>0$ to $2$  & 410 & 0.98 & (0.83, 1.15) &  & 258 & 0.91 & (0.74, 1.11) &  & 0.88 & (0.72, 1.09) &  & 0.88 & (0.72, 1.09) \\ 
   & $>2$ & 214 & 1.06 & (0.89, 1.27) &  & 135 & 0.92 & (0.74, 1.15) &  & 0.92 & (0.73, 1.15) &  & 0.92 & (0.73, 1.15) \\ 
  \multicolumn{3}{l}{Lag 5}\\
  & $0$ & 487 &  &  &  & 297 &  &  &  &  &  &  &  &  \\ 
   & $>0$ to $2$  & 417 & 0.96 & (0.82, 1.13) &  & 256 & 0.87 & (0.71, 1.06) &  & 0.85 & (0.69, 1.04) &  & 0.85 & (0.69, 1.04) \\ 
   & $>2$ & 227 & 1.05 & (0.88, 1.25) &  & 141 & 0.92 & (0.74, 1.15) &  & 0.92 & (0.74, 1.16) &  & 0.92 & (0.74, 1.15) \\ 
   \bottomrule
\end{tabular}
\end{adjustbox}\end{table}

# 

## Lung cancer (exposure lagged 21 years)

\begin{table}\linespread{1.15}
\begin{adjustbox}{scale = 0.7}
%\caption{Adjusted HR estimates for lung cancer.}
\begin{tabular}{llrlllrllllllll}
  \toprule & & \multicolumn{3}{c}{Full follow-up}& & \multicolumn{3}{c}{1985 cohort}& & \multicolumn{2}{c}{Weighted by surv.}& & \multicolumn{2}{c}{St. inverse weight}\\
\cline{3-5} \cline{7-9} \cline{11-12} \cline{14-15}
\vspace{0em} & \vspace{0em} & $n$ & HR & 95\% CI &   & $n$ & HR & 95\% CI &   & HR & 95\% CI &   & HR & 95\% CI \\ 
  \midrule
\multicolumn{3}{l}{Straight}\\
 & $0$ & 648 &  &  &  & 360 &  &  &  &  &  &  &  &  \\ 
   & $>0$ to $2$  & 333 & 0.94 & (0.79, 1.11) &  & 222 & 0.79 & (0.64, 0.98) &  & 0.77 & (0.62, 0.95) &  & 0.78 & (0.63, 0.97) \\ 
   & $>2$ & 150 & 0.96 & (0.79, 1.17) &  & 112 & 0.86 & (0.68, 1.09) &  & 0.85 & (0.67, 1.09) &  & 0.85 & (0.67, 1.08) \\ 
  \multicolumn{3}{l}{Soluble}\\
 & $0$ to $0.05$ & 339 &  &  &  & 139 &  &  &  &  &  &  &  &  \\ 
   & $>0.05$ to $4$  & 264 & 0.88 & (0.73, 1.07) &  & 164 & 0.99 & (0.77, 1.26) &  & 0.96 & (0.75, 1.22) &  & 0.99 & (0.77, 1.27) \\ 
   & $>4$ to $12.6$  & 264 & 0.84 & (0.69, 1.02) &  & 187 & 1.11 & (0.85, 1.44) &  & 1.11 & (0.86, 1.45) &  & 1.14 & (0.87, 1.49) \\ 
   & $>12.6$ & 264 & 0.93 & (0.75, 1.14) &  & 204 & 1.11 & (0.85, 1.45) &  & 1.10 & (0.84, 1.45) &  & 1.10 & (0.83, 1.44) \\ 
  \multicolumn{3}{l}{Synthetic}\\
 & $0$ & 884 &  &  &  & 509 &  &  &  &  &  &  &  &  \\ 
   & $>0$ to $0.4$  &  83 & 1.00 & (0.77, 1.29) &  &  58 & 1.03 & (0.75, 1.40) &  & 1.02 & (0.74, 1.40) &  & 1.01 & (0.73, 1.40) \\ 
   & $>0.4$ to $1.5$  &  82 & 1.20 & (0.92, 1.57) &  &  58 & 1.26 & (0.91, 1.74) &  & 1.26 & (0.91, 1.74) &  & 1.27 & (0.92, 1.76) \\ 
   & $>1.5$ &  82 & 0.95 & (0.74, 1.22) &  &  69 & 0.95 & (0.71, 1.25) &  & 0.93 & (0.70, 1.24) &  & 0.96 & (0.72, 1.27) \\ 
   \bottomrule
\end{tabular}
\end{adjustbox}\end{table}


# 

## Lung cancer (exposure lagged 10 years)

\begin{table}\linespread{1.15}
\begin{adjustbox}{scale = 0.7}
%\caption{Adjusted HR estimates for lung cancer.}
\begin{tabular}{llrlllrllllllll}
  \toprule & & \multicolumn{3}{c}{Full follow-up}& & \multicolumn{3}{c}{1985 cohort}& & \multicolumn{2}{c}{Weighted by surv.}& & \multicolumn{2}{c}{St. inverse weight}\\
\cline{3-5} \cline{7-9} \cline{11-12} \cline{14-15}
\vspace{0em} & \vspace{0em} & $n$ & HR & 95\% CI &   & $n$ & HR & 95\% CI &   & HR & 95\% CI &   & HR & 95\% CI \\ 
  \midrule
\multicolumn{3}{l}{Straight}\\
 & $0$ & 507 &  &  &  & 301 &  &  &  &  &  &  &  &  \\ 
   & $>0$ to $2$  & 410 & 0.98 & (0.83, 1.15) &  & 258 & 0.91 & (0.74, 1.11) &  & 0.88 & (0.72, 1.09) &  & 0.88 & (0.72, 1.09) \\ 
   & $>2$ & 214 & 1.06 & (0.89, 1.27) &  & 135 & 0.92 & (0.74, 1.15) &  & 0.92 & (0.73, 1.15) &  & 0.92 & (0.73, 1.15) \\ 
  \multicolumn{3}{l}{Soluble}\\
 & $0$ to $0.05$ & 172 &  &  &  &  91 &  &  &  &  &  &  &  &  \\ 
   & $>0.05$ to $4.8$  & 320 & 0.80 & (0.65, 0.98) &  & 204 & 0.79 & (0.61, 1.03) &  & 0.76 & (0.58, 0.98) &  & 0.81 & (0.62, 1.06) \\ 
   & $>4.8$ to $15.3$  & 319 & 0.84 & (0.68, 1.03) &  & 194 & 0.89 & (0.68, 1.16) &  & 0.85 & (0.65, 1.12) &  & 0.91 & (0.69, 1.20) \\ 
   & $>15.3$ & 320 & 0.89 & (0.72, 1.11) &  & 205 & 0.93 & (0.71, 1.22) &  & 0.89 & (0.68, 1.18) &  & 0.92 & (0.69, 1.22) \\ 
  \multicolumn{3}{l}{Synthetic}\\
 & $0$ & 794 &  &  &  & 463 &  &  &  &  &  &  &  &  \\ 
   & $>0$ to $0.4$  & 113 & 1.07 & (0.85, 1.35) &  &  76 & 1.09 & (0.82, 1.45) &  & 1.11 & (0.83, 1.48) &  & 1.10 & (0.82, 1.49) \\ 
   & $>0.4$ to $1.4$  & 112 & 1.21 & (0.96, 1.53) &  &  71 & 1.24 & (0.93, 1.66) &  & 1.25 & (0.92, 1.68) &  & 1.27 & (0.94, 1.70) \\ 
   & $>1.4$ & 112 & 0.82 & (0.66, 1.03) &  &  84 & 0.92 & (0.70, 1.19) &  & 0.91 & (0.70, 1.19) &  & 0.92 & (0.70, 1.20) \\ 
   \bottomrule
\end{tabular}
\end{adjustbox}\end{table}


# 

## Lung cancer (exposure lagged 5 years)

\begin{table}\linespread{1.15}
\begin{adjustbox}{scale = 0.7}
%\caption{Adjusted HR estimates for lung cancer.}
\begin{tabular}{llrlllrllllllll}
  \toprule & & \multicolumn{3}{c}{Full follow-up}& & \multicolumn{3}{c}{1985 cohort}& & \multicolumn{2}{c}{Weighted by surv.}& & \multicolumn{2}{c}{St. inverse weight}\\
\cline{3-5} \cline{7-9} \cline{11-12} \cline{14-15}
\vspace{0em} & \vspace{0em} & $n$ & HR & 95\% CI &   & $n$ & HR & 95\% CI &   & HR & 95\% CI &   & HR & 95\% CI \\ 
  \midrule
\multicolumn{3}{l}{Straight}\\
 & $0$ & 487 &  &  &  & 297 &  &  &  &  &  &  &  &  \\ 
   & $>0$ to $2$  & 417 & 0.96 & (0.82, 1.13) &  & 256 & 0.87 & (0.71, 1.06) &  & 0.85 & (0.69, 1.04) &  & 0.85 & (0.69, 1.04) \\ 
   & $>2$ & 227 & 1.05 & (0.88, 1.25) &  & 141 & 0.92 & (0.74, 1.15) &  & 0.92 & (0.74, 1.16) &  & 0.92 & (0.74, 1.15) \\ 
  \multicolumn{3}{l}{Soluble}\\
 & $0$ to $0.05$ & 142 &  &  &  &  82 &  &  &  &  &  &  &  &  \\ 
   & $>0.05$ to $4.9$  & 330 & 0.80 & (0.65, 0.99) &  & 213 & 0.86 & (0.66, 1.13) &  & 0.83 & (0.64, 1.09) &  & 0.82 & (0.62, 1.08) \\ 
   & $>4.9$ to $16.1$  & 329 & 0.78 & (0.63, 0.97) &  & 202 & 0.89 & (0.67, 1.17) &  & 0.85 & (0.64, 1.12) &  & 0.86 & (0.64, 1.14) \\ 
   & $>16.1$ & 330 & 0.87 & (0.70, 1.09) &  & 197 & 0.93 & (0.70, 1.24) &  & 0.90 & (0.67, 1.19) &  & 0.87 & (0.65, 1.16) \\ 
  \multicolumn{3}{l}{Synthetic}\\
 & $0$ & 779 &  &  &  & 455 &  &  &  &  &  &  &  &  \\ 
   & $>0$ to $0.4$  & 118 & 1.00 & (0.80, 1.25) &  &  77 & 1.05 & (0.79, 1.40) &  & 1.04 & (0.78, 1.38) &  & 0.99 & (0.74, 1.32) \\ 
   & $>0.4$ to $1.6$  & 117 & 1.14 & (0.91, 1.44) &  &  79 & 1.31 & (0.99, 1.75) &  & 1.33 & (1.00, 1.78) &  & 1.35 & (1.01, 1.82) \\ 
   & $>1.6$ & 117 & 0.83 & (0.67, 1.03) &  &  83 & 0.93 & (0.71, 1.21) &  & 0.93 & (0.71, 1.21) &  & 0.92 & (0.71, 1.21) \\ 
   \bottomrule
\end{tabular}
\end{adjustbox}\end{table}

# 

## Stomach cancer (straight MWF, FU through 1999)

\begin{table}\linespread{1.15}
\begin{adjustbox}{scale = 0.7}
%\caption{Adjusted HR estimates for stomach cancer.}
\begin{tabular}{llrlllrllllllll}
  \toprule & & \multicolumn{3}{c}{Full follow-up}& & \multicolumn{3}{c}{1985 cohort}& & \multicolumn{2}{c}{Weighted by surv.}& & \multicolumn{2}{c}{St. inverse weight}\\
\cline{3-5} \cline{7-9} \cline{11-12} \cline{14-15}
\vspace{0em} & \vspace{0em} & $n$ & HR & 95\% CI &   & $n$ & HR & 95\% CI &   & HR & 95\% CI &   & HR & 95\% CI \\ 
  \midrule
\multicolumn{3}{l}{Lag 21}\\
 & $0$ &  78 &  &  &  &  29 &  &  &  &  &  &  &  &  \\ 
   & $>0$ to $2$  &  28 & 0.84 & (0.48, 1.46) &  &  17 & 0.97 & (0.45, 2.09) &  & 0.80 & (0.36, 1.74) &  & 0.93 & (0.41, 2.08) \\ 
   & $>2$ &  18 & 1.31 & (0.77, 2.24) &  &  11 & 1.27 & (0.61, 2.61) &  & 1.20 & (0.58, 2.50) &  & 1.37 & (0.66, 2.86) \\ 
  \multicolumn{3}{l}{Lag 10}\\
  & $0$ &  55 &  &  &  &  22 &  &  &  &  &  &  &  &  \\ 
   & $>0$ to $2$  &  43 & 1.17 & (0.71, 1.93) &  &  22 & 1.40 & (0.68, 2.92) &  & 1.32 & (0.62, 2.83) &  & 1.40 & (0.65, 3.03) \\ 
   & $>2$ &  26 & 1.53 & (0.93, 2.51) &  &  13 & 1.51 & (0.72, 3.18) &  & 1.53 & (0.71, 3.31) &  & 1.66 & (0.77, 3.55) \\ 
  \multicolumn{3}{l}{Lag 5}\\
  & $0$ &  51 &  &  &  &  21 &  &  &  &  &  &  &  &  \\ 
   & $>0$ to $2$  &  47 & 1.24 & (0.77, 1.98) &  &  23 & 1.49 & (0.73, 3.05) &  & 1.42 & (0.68, 3.00) &  & 1.45 & (0.69, 3.03) \\ 
   & $>2$ &  26 & 1.39 & (0.86, 2.26) &  &  13 & 1.50 & (0.72, 3.15) &  & 1.52 & (0.71, 3.26) &  & 1.62 & (0.77, 3.44) \\ 
   \bottomrule
\end{tabular}
\end{adjustbox}\end{table}

# 

## Stomach cancer (exposure lagged 21 years)

\begin{table}\linespread{1.15}
\begin{adjustbox}{scale = 0.7}
%\caption{Adjusted HR estimates for stomach cancer.}
\begin{tabular}{llrlllrllllllll}
  \toprule & & \multicolumn{3}{c}{Full follow-up}& & \multicolumn{3}{c}{1985 cohort}& & \multicolumn{2}{c}{Weighted by surv.}& & \multicolumn{2}{c}{St. inverse weight}\\
\cline{3-5} \cline{7-9} \cline{11-12} \cline{14-15}
\vspace{0em} & \vspace{0em} & $n$ & HR & 95\% CI &   & $n$ & HR & 95\% CI &   & HR & 95\% CI &   & HR & 95\% CI \\ 
  \midrule
\multicolumn{3}{l}{Straight}\\
 & $0$ &  78 &  &  &  &  29 &  &  &  &  &  &  &  &  \\ 
   & $>0$ to $2$  &  28 & 0.84 & (0.48, 1.46) &  &  17 & 0.97 & (0.45, 2.09) &  & 0.80 & (0.36, 1.74) &  & 0.93 & (0.41, 2.08) \\ 
   & $>2$ &  18 & 1.31 & (0.77, 2.24) &  &  11 & 1.27 & (0.61, 2.61) &  & 1.20 & (0.58, 2.50) &  & 1.37 & (0.66, 2.86) \\ 
  \multicolumn{3}{l}{Soluble}\\
 & $0$ to $0.05$ &  48 &  &  &  &  15 &  &  &  &  &  &  &  &  \\ 
   & $>0.05$ to $4.4$  &  25 & 0.60 & (0.35, 1.04) &  &   5 & 0.22 & (0.08, 0.64) &  & 0.22 & (0.07, 0.66) &  & 0.25 & (0.08, 0.74) \\ 
   & $>4.4$ to $9.3$  &  25 & 0.95 & (0.54, 1.67) &  &  16 & 1.11 & (0.48, 2.58) &  & 1.16 & (0.49, 2.72) &  & 1.14 & (0.47, 2.74) \\ 
   & $>9.3$ &  26 & 0.47 & (0.27, 0.82) &  &  21 & 0.60 & (0.28, 1.31) &  & 0.59 & (0.27, 1.27) &  & 0.63 & (0.28, 1.44) \\ 
  \multicolumn{3}{l}{Synthetic}\\
 & $0$ & 105 &  &  &  &  44 &  &  &  &  &  &  &  &  \\ 
   & $>0$ to $0.3$  &  10 & 1.44 & (0.68, 3.05) &  &   5 & 1.24 & (0.43, 3.55) &  & 1.10 & (0.36, 3.29) &  & 1.05 & (0.34, 3.24) \\ 
   & $>0.3$ &   9 & 0.60 & (0.27, 1.34) &  &   8 & 0.63 & (0.24, 1.66) &  & 0.66 & (0.26, 1.70) &  & 0.64 & (0.24, 1.71) \\ 
   \bottomrule
\end{tabular}
\end{adjustbox}\end{table}

# 

## Stomach cancer (exposure lagged 10 years)

\begin{table}\linespread{1.15}
\begin{adjustbox}{scale = 0.7}
%\caption{Adjusted HR estimates for stomach cancer.}
\begin{tabular}{llrlllrllllllll}
  \toprule & & \multicolumn{3}{c}{Full follow-up}& & \multicolumn{3}{c}{1985 cohort}& & \multicolumn{2}{c}{Weighted by surv.}& & \multicolumn{2}{c}{St. inverse weight}\\
\cline{3-5} \cline{7-9} \cline{11-12} \cline{14-15}
\vspace{0em} & \vspace{0em} & $n$ & HR & 95\% CI &   & $n$ & HR & 95\% CI &   & HR & 95\% CI &   & HR & 95\% CI \\ 
  \midrule
\multicolumn{3}{l}{Straight}\\
 & $0$ &  55 &  &  &  &  22 &  &  &  &  &  &  &  &  \\ 
   & $>0$ to $2$  &  43 & 1.17 & (0.71, 1.93) &  &  22 & 1.40 & (0.68, 2.92) &  & 1.32 & (0.62, 2.83) &  & 1.40 & (0.65, 3.03) \\ 
   & $>2$ &  26 & 1.53 & (0.93, 2.51) &  &  13 & 1.51 & (0.72, 3.18) &  & 1.53 & (0.71, 3.31) &  & 1.66 & (0.77, 3.55) \\ 
  \multicolumn{3}{l}{Soluble}\\
 & $0$ to $0.05$ &  21 &  &  &  &   9 &  &  &  &  &  &  &  &  \\ 
   & $>0.05$ to $5.1$  &  33 & 0.68 & (0.37, 1.24) &  &  12 & 0.41 & (0.16, 1.07) &  & 0.47 & (0.17, 1.27) &  & 0.50 & (0.18, 1.40) \\ 
   & $>5.1$ to $12.5$  &  35 & 0.97 & (0.53, 1.77) &  &  17 & 0.96 & (0.38, 2.41) &  & 0.98 & (0.38, 2.51) &  & 1.04 & (0.39, 2.81) \\ 
   & $>12.5$ &  35 & 0.59 & (0.32, 1.10) &  &  19 & 0.60 & (0.24, 1.48) &  & 0.60 & (0.24, 1.54) &  & 0.66 & (0.25, 1.78) \\ 
  \multicolumn{3}{l}{Synthetic}\\
 & $0$ &  96 &  &  &  &  42 &  &  &  &  &  &  &  &  \\ 
   & $>0$ to $0.3$  &  14 & 1.24 & (0.65, 2.38) &  &   7 & 1.09 & (0.40, 2.97) &  & 0.86 & (0.30, 2.52) &  & 0.97 & (0.34, 2.75) \\ 
   & $>0.3$ &  14 & 0.46 & (0.24, 0.88) &  &   8 & 0.41 & (0.16, 1.03) &  & 0.38 & (0.15, 0.97) &  & 0.41 & (0.16, 1.05) \\ 
   \bottomrule
\end{tabular}
\end{adjustbox}\end{table}


# 

## Stomach cancer (exposure lagged 5 years)

\begin{table}\linespread{1.15}
\begin{adjustbox}{scale = 0.7}
%\caption{Adjusted HR estimates for stomach cancer.}
\begin{tabular}{llrlllrllllllll}
  \toprule & & \multicolumn{3}{c}{Full follow-up}& & \multicolumn{3}{c}{1985 cohort}& & \multicolumn{2}{c}{Weighted by surv.}& & \multicolumn{2}{c}{St. inverse weight}\\
\cline{3-5} \cline{7-9} \cline{11-12} \cline{14-15}
\vspace{0em} & \vspace{0em} & $n$ & HR & 95\% CI &   & $n$ & HR & 95\% CI &   & HR & 95\% CI &   & HR & 95\% CI \\ 
  \midrule
\multicolumn{3}{l}{Straight}\\
 & $0$ &  51 &  &  &  &  21 &  &  &  &  &  &  &  &  \\ 
   & $>0$ to $2$  &  47 & 1.24 & (0.77, 1.98) &  &  23 & 1.49 & (0.73, 3.05) &  & 1.42 & (0.68, 3.00) &  & 1.45 & (0.69, 3.03) \\ 
   & $>2$ &  26 & 1.39 & (0.86, 2.26) &  &  13 & 1.50 & (0.72, 3.15) &  & 1.52 & (0.71, 3.26) &  & 1.62 & (0.77, 3.44) \\ 
  \multicolumn{3}{l}{Soluble}\\
 & $0$ to $0.05$ &  15 &  &  &  &   9 &  &  &  &  &  &  &  &  \\ 
   & $>0.05$ to $5.2$  &  34 & 0.71 & (0.37, 1.34) &  &  13 & 0.37 & (0.14, 0.92) &  & 0.41 & (0.16, 1.06) &  & 0.40 & (0.16, 1.01) \\ 
   & $>5.2$ to $13.4$  &  37 & 0.95 & (0.50, 1.81) &  &  16 & 0.73 & (0.30, 1.80) &  & 0.71 & (0.28, 1.77) &  & 0.73 & (0.29, 1.84) \\ 
   & $>13.4$ &  38 & 0.65 & (0.34, 1.26) &  &  19 & 0.54 & (0.22, 1.31) &  & 0.54 & (0.22, 1.34) &  & 0.56 & (0.22, 1.39) \\ 
  \multicolumn{3}{l}{Synthetic}\\
 & $0$ &  94 &  &  &  &  41 &  &  &  &  &  &  &  &  \\ 
   & $>0$ to $0.4$  &  15 & 0.91 & (0.48, 1.72) &  &   9 & 1.06 & (0.43, 2.62) &  & 0.85 & (0.33, 2.24) &  & 0.93 & (0.36, 2.40) \\ 
   & $>0.4$ &  15 & 0.46 & (0.24, 0.88) &  &   7 & 0.39 & (0.15, 1.01) &  & 0.37 & (0.14, 0.98) &  & 0.39 & (0.15, 1.03) \\ 
   \bottomrule
\end{tabular}
\end{adjustbox}\end{table}

# 

## Prostate cancer (straight MWF, FU through 1999)

\begin{table}\linespread{1.15}
\begin{adjustbox}{scale = 0.7}
%\caption{Adjusted HR estimates for prostate cancer.}
\begin{tabular}{llrlllrllllllll}
  \toprule & & \multicolumn{3}{c}{Full follow-up}& & \multicolumn{3}{c}{1985 cohort}& & \multicolumn{2}{c}{Weighted by surv.}& & \multicolumn{2}{c}{St. inverse weight}\\
\cline{3-5} \cline{7-9} \cline{11-12} \cline{14-15}
\vspace{0em} & \vspace{0em} & $n$ & HR & 95\% CI &   & $n$ & HR & 95\% CI &   & HR & 95\% CI &   & HR & 95\% CI \\ 
  \midrule
\multicolumn{3}{l}{Lag 21}\\
 & $0$ & 116 &  &  &  &  77 &  &  &  &  &  &  &  &  \\ 
   & $>0$ to $2$  &  75 & 1.08 & (0.75, 1.57) &  &  58 & 0.95 & (0.62, 1.44) &  & 0.98 & (0.64, 1.51) &  & 0.92 & (0.60, 1.41) \\ 
   & $>2$ &  42 & 1.20 & (0.81, 1.78) &  &  33 & 1.07 & (0.69, 1.65) &  & 1.10 & (0.70, 1.72) &  & 1.05 & (0.67, 1.63) \\ 
  \multicolumn{3}{l}{Lag 10}\\
  & $0$ & 103 &  &  &  &  75 &  &  &  &  &  &  &  &  \\ 
   & $>0$ to $2$  &  79 & 0.94 & (0.66, 1.34) &  &  57 & 0.83 & (0.55, 1.26) &  & 0.81 & (0.53, 1.24) &  & 0.82 & (0.54, 1.25) \\ 
   & $>2$ &  51 & 1.10 & (0.76, 1.58) &  &  36 & 0.93 & (0.61, 1.41) &  & 0.92 & (0.60, 1.41) &  & 0.90 & (0.59, 1.38) \\ 
  \multicolumn{3}{l}{Lag 5}\\
  & $0$ & 100 &  &  &  &  75 &  &  &  &  &  &  &  &  \\ 
   & $>0$ to $2$  &  81 & 0.95 & (0.67, 1.35) &  &  57 & 0.81 & (0.54, 1.22) &  & 0.78 & (0.51, 1.19) &  & 0.79 & (0.52, 1.21) \\ 
   & $>2$ &  52 & 1.10 & (0.77, 1.57) &  &  36 & 0.90 & (0.60, 1.36) &  & 0.89 & (0.59, 1.36) &  & 0.88 & (0.58, 1.33) \\ 
   \bottomrule
\end{tabular}
\end{adjustbox}\end{table}


# 

## Prostate cancer (exposure lagged 21 years)

\begin{table}\linespread{1.15}
\begin{adjustbox}{scale = 0.7}
%\caption{Adjusted HR estimates for prostate cancer.}
\begin{tabular}{llrlllrllllllll}
  \toprule & & \multicolumn{3}{c}{Full follow-up}& & \multicolumn{3}{c}{1985 cohort}& & \multicolumn{2}{c}{Weighted by surv.}& & \multicolumn{2}{c}{St. inverse weight}\\
\cline{3-5} \cline{7-9} \cline{11-12} \cline{14-15}
\vspace{0em} & \vspace{0em} & $n$ & HR & 95\% CI &   & $n$ & HR & 95\% CI &   & HR & 95\% CI &   & HR & 95\% CI \\ 
  \midrule
\multicolumn{3}{l}{Straight}\\
 & $0$ & 116 &  &  &  &  77 &  &  &  &  &  &  &  &  \\ 
   & $>0$ to $2$  &  75 & 1.08 & (0.75, 1.57) &  &  58 & 0.95 & (0.62, 1.44) &  & 0.98 & (0.64, 1.51) &  & 0.92 & (0.60, 1.41) \\ 
   & $>2$ &  42 & 1.20 & (0.81, 1.78) &  &  33 & 1.07 & (0.69, 1.65) &  & 1.10 & (0.70, 1.72) &  & 1.05 & (0.67, 1.63) \\ 
  \multicolumn{3}{l}{Soluble}\\
 & $0$ to $0.05$ &  50 &  &  &  &  26 &  &  &  &  &  &  &  &  \\ 
   & $>0.05$ to $6$  &  61 & 0.65 & (0.43, 0.98) &  &  44 & 0.64 & (0.38, 1.08) &  & 0.63 & (0.37, 1.07) &  & 0.62 & (0.37, 1.06) \\ 
   & $>6$ to $17.5$  &  61 & 0.65 & (0.42, 1.00) &  &  49 & 0.66 & (0.39, 1.12) &  & 0.65 & (0.38, 1.09) &  & 0.65 & (0.38, 1.11) \\ 
   & $>17.5$ &  61 & 0.72 & (0.45, 1.14) &  &  49 & 0.66 & (0.38, 1.14) &  & 0.67 & (0.39, 1.18) &  & 0.66 & (0.38, 1.14) \\ 
  \multicolumn{3}{l}{Synthetic}\\
 & $0$ & 174 &  &  &  & 116 &  &  &  &  &  &  &  &  \\ 
   & $>0$ to $1.5$  &  30 & 1.11 & (0.67, 1.82) &  &  26 & 1.43 & (0.81, 2.55) &  & 1.41 & (0.77, 2.56) &  & 1.42 & (0.79, 2.56) \\ 
   & $>1.5$ &  29 & 1.74 & (1.09, 2.76) &  &  26 & 1.90 & (1.13, 3.22) &  & 1.85 & (1.08, 3.18) &  & 1.88 & (1.10, 3.22) \\ 
   \bottomrule
\end{tabular}
\end{adjustbox}\end{table}


# 

## Prostate cancer (exposure lagged 10 years)

\begin{table}\linespread{1.15}
\begin{adjustbox}{scale = 0.7}
%\caption{Adjusted HR estimates for prostate cancer.}
\begin{tabular}{llrlllrllllllll}
  \toprule & & \multicolumn{3}{c}{Full follow-up}& & \multicolumn{3}{c}{1985 cohort}& & \multicolumn{2}{c}{Weighted by surv.}& & \multicolumn{2}{c}{St. inverse weight}\\
\cline{3-5} \cline{7-9} \cline{11-12} \cline{14-15}
\vspace{0em} & \vspace{0em} & $n$ & HR & 95\% CI &   & $n$ & HR & 95\% CI &   & HR & 95\% CI &   & HR & 95\% CI \\ 
  \midrule
\multicolumn{3}{l}{Straight}\\
 & $0$ & 103 &  &  &  &  75 &  &  &  &  &  &  &  &  \\ 
   & $>0$ to $2$  &  79 & 0.94 & (0.66, 1.34) &  &  57 & 0.83 & (0.55, 1.26) &  & 0.81 & (0.53, 1.24) &  & 0.82 & (0.54, 1.25) \\ 
   & $>2$ &  51 & 1.10 & (0.76, 1.58) &  &  36 & 0.93 & (0.61, 1.41) &  & 0.92 & (0.60, 1.41) &  & 0.90 & (0.59, 1.38) \\ 
  \multicolumn{3}{l}{Soluble}\\
 & $0$ to $0.05$ &  29 &  &  &  &  20 &  &  &  &  &  &  &  &  \\ 
   & $>0.05$ to $7$  &  68 & 0.63 & (0.40, 0.99) &  &  46 & 0.59 & (0.34, 1.01) &  & 0.58 & (0.34, 1.00) &  & 0.57 & (0.33, 0.99) \\ 
   & $>7$ to $19.7$  &  68 & 0.65 & (0.40, 1.04) &  &  54 & 0.72 & (0.42, 1.25) &  & 0.72 & (0.41, 1.25) &  & 0.71 & (0.40, 1.24) \\ 
   & $>19.7$ &  68 & 0.66 & (0.41, 1.07) &  &  48 & 0.62 & (0.36, 1.08) &  & 0.64 & (0.37, 1.11) &  & 0.63 & (0.36, 1.09) \\ 
  \multicolumn{3}{l}{Synthetic}\\
 & $0$ & 161 &  &  &  & 111 &  &  &  &  &  &  &  &  \\ 
   & $>0$ to $0.6$  &  24 & 1.40 & (0.81, 2.42) &  &  17 & 1.55 & (0.79, 3.03) &  & 1.76 & (0.87, 3.55) &  & 1.56 & (0.79, 3.09) \\ 
   & $>0.6$ to $2.2$  &  24 & 1.31 & (0.78, 2.21) &  &  20 & 1.57 & (0.85, 2.91) &  & 1.54 & (0.81, 2.93) &  & 1.48 & (0.79, 2.79) \\ 
   & $>2.2$ &  24 & 1.60 & (1.00, 2.58) &  &  20 & 1.77 & (1.04, 3.03) &  & 1.72 & (0.99, 2.99) &  & 1.70 & (0.98, 2.95) \\ 
   \bottomrule
\end{tabular}
\end{adjustbox}\end{table}


# 

## Prostate cancer (exposure lagged 5 years)

\begin{table}\linespread{1.15}
\begin{adjustbox}{scale = 0.7}
%\caption{Adjusted HR estimates for prostate cancer.}
\begin{tabular}{llrlllrllllllll}
  \toprule & & \multicolumn{3}{c}{Full follow-up}& & \multicolumn{3}{c}{1985 cohort}& & \multicolumn{2}{c}{Weighted by surv.}& & \multicolumn{2}{c}{St. inverse weight}\\
\cline{3-5} \cline{7-9} \cline{11-12} \cline{14-15}
\vspace{0em} & \vspace{0em} & $n$ & HR & 95\% CI &   & $n$ & HR & 95\% CI &   & HR & 95\% CI &   & HR & 95\% CI \\ 
  \midrule
\multicolumn{3}{l}{Straight}\\
 & $0$ & 100 &  &  &  &  75 &  &  &  &  &  &  &  &  \\ 
   & $>0$ to $2$  &  81 & 0.95 & (0.67, 1.35) &  &  57 & 0.81 & (0.54, 1.22) &  & 0.78 & (0.51, 1.19) &  & 0.79 & (0.52, 1.21) \\ 
   & $>2$ &  52 & 1.10 & (0.77, 1.57) &  &  36 & 0.90 & (0.60, 1.36) &  & 0.89 & (0.59, 1.36) &  & 0.88 & (0.58, 1.33) \\ 
  \multicolumn{3}{l}{Soluble}\\
 & $0$ to $0.05$ &  26 &  &  &  &  19 &  &  &  &  &  &  &  &  \\ 
   & $>0.05$ to $7.1$  &  69 & 0.63 & (0.39, 1.00) &  &  47 & 0.61 & (0.35, 1.05) &  & 0.61 & (0.35, 1.05) &  & 0.59 & (0.34, 1.02) \\ 
   & $>7.1$ to $19.2$  &  69 & 0.67 & (0.41, 1.07) &  &  53 & 0.76 & (0.43, 1.32) &  & 0.77 & (0.44, 1.35) &  & 0.73 & (0.41, 1.28) \\ 
   & $>19.2$ &  69 & 0.62 & (0.38, 1.00) &  &  49 & 0.63 & (0.36, 1.09) &  & 0.64 & (0.36, 1.11) &  & 0.63 & (0.36, 1.10) \\ 
  \multicolumn{3}{l}{Synthetic}\\
 & $0$ & 159 &  &  &  & 110 &  &  &  &  &  &  &  &  \\ 
   & $>0$ to $0.6$  &  25 & 1.44 & (0.83, 2.48) &  &  18 & 1.67 & (0.86, 3.24) &  & 1.96 & (0.98, 3.90) &  & 1.68 & (0.85, 3.29) \\ 
   & $>0.6$ to $2.1$  &  24 & 1.29 & (0.77, 2.18) &  &  19 & 1.57 & (0.84, 2.92) &  & 1.54 & (0.80, 2.95) &  & 1.47 & (0.77, 2.79) \\ 
   & $>2.1$ &  25 & 1.52 & (0.95, 2.44) &  &  21 & 1.76 & (1.03, 3.00) &  & 1.71 & (0.99, 2.98) &  & 1.68 & (0.97, 2.91) \\ 
   \bottomrule
\end{tabular}
\end{adjustbox}\end{table}

# 

## Non-Hodgkin lymphoma (straight MWF, FU through 1999)

\begin{table}\linespread{1.15}
\begin{adjustbox}{scale = 0.7}
%\caption{Adjusted HR estimates for non-hodgkin lymphoma.}
\begin{tabular}{llrlllrllllllll}
  \toprule & & \multicolumn{3}{c}{Full follow-up}& & \multicolumn{3}{c}{1985 cohort}& & \multicolumn{2}{c}{Weighted by surv.}& & \multicolumn{2}{c}{St. inverse weight}\\
\cline{3-5} \cline{7-9} \cline{11-12} \cline{14-15}
\vspace{0em} & \vspace{0em} & $n$ & HR & 95\% CI &   & $n$ & HR & 95\% CI &   & HR & 95\% CI &   & HR & 95\% CI \\ 
  \midrule
\multicolumn{3}{l}{Lag 21}\\
 & $0$ &  43 &  &  &  &  23 &  &  &  &  &  &  &  &  \\ 
   & $>0$ to $2$  &  33 & 1.11 & (0.59, 2.08) &  &  24 & 1.50 & (0.72, 3.10) &  & 1.60 & (0.76, 3.36) &  & 1.51 & (0.73, 3.16) \\ 
   & $>2$ &  14 & 1.06 & (0.54, 2.11) &  &  11 & 1.35 & (0.60, 3.05) &  & 1.41 & (0.62, 3.20) &  & 1.37 & (0.60, 3.10) \\ 
  \multicolumn{3}{l}{Lag 10}\\
  & $0$ &  39 &  &  &  &  22 &  &  &  &  &  &  &  &  \\ 
   & $>0$ to $2$  &  30 & 0.83 & (0.45, 1.53) &  &  20 & 0.92 & (0.45, 1.90) &  & 0.93 & (0.44, 1.94) &  & 0.94 & (0.45, 1.94) \\ 
   & $>2$ &  21 & 1.15 & (0.66, 2.00) &  &  16 & 1.37 & (0.70, 2.68) &  & 1.41 & (0.72, 2.77) &  & 1.38 & (0.71, 2.71) \\ 
  \multicolumn{3}{l}{Lag 5}\\
  & $0$ &  39 &  &  &  &  22 &  &  &  &  &  &  &  &  \\ 
   & $>0$ to $2$  &  29 & 0.75 & (0.42, 1.36) &  &  20 & 0.94 & (0.46, 1.89) &  & 0.94 & (0.46, 1.92) &  & 0.94 & (0.46, 1.91) \\ 
   & $>2$ &  22 & 1.07 & (0.63, 1.84) &  &  16 & 1.31 & (0.68, 2.54) &  & 1.34 & (0.69, 2.61) &  & 1.31 & (0.68, 2.55) \\ 
   \bottomrule
\end{tabular}
\end{adjustbox}\end{table}


# 

## Non-Hodgkin lymphoma (exposure lagged 21 years)

\begin{table}\linespread{1.15}
\begin{adjustbox}{scale = 0.7}
%\caption{Adjusted HR estimates for non-hodgkin lymphoma.}
\begin{tabular}{llrlllrllllllll}
  \toprule & & \multicolumn{3}{c}{Full follow-up}& & \multicolumn{3}{c}{1985 cohort}& & \multicolumn{2}{c}{Weighted by surv.}& & \multicolumn{2}{c}{St. inverse weight}\\
\cline{3-5} \cline{7-9} \cline{11-12} \cline{14-15}
\vspace{0em} & \vspace{0em} & $n$ & HR & 95\% CI &   & $n$ & HR & 95\% CI &   & HR & 95\% CI &   & HR & 95\% CI \\ 
  \midrule
\multicolumn{3}{l}{Straight}\\
 & $0$ &  43 &  &  &  &  23 &  &  &  &  &  &  &  &  \\ 
   & $>0$ to $2$  &  33 & 1.11 & (0.59, 2.08) &  &  24 & 1.50 & (0.72, 3.10) &  & 1.60 & (0.76, 3.36) &  & 1.51 & (0.73, 3.16) \\ 
   & $>2$ &  14 & 1.06 & (0.54, 2.11) &  &  11 & 1.35 & (0.60, 3.05) &  & 1.41 & (0.62, 3.20) &  & 1.37 & (0.60, 3.10) \\ 
  \multicolumn{3}{l}{Soluble}\\
 & $0$ to $0.05$ &  17 &  &  &  &   8 &  &  &  &  &  &  &  &  \\ 
   & $>0.05$ to $4.4$  &  23 & 1.67 & (0.79, 3.51) &  &  14 & 1.20 & (0.43, 3.34) &  & 1.14 & (0.39, 3.29) &  & 1.34 & (0.46, 3.92) \\ 
   & $>4.4$ to $12.1$  &  24 & 2.20 & (0.95, 5.10) &  &  16 & 1.63 & (0.51, 5.21) &  & 1.54 & (0.47, 5.10) &  & 1.79 & (0.54, 6.01) \\ 
   & $>12.1$ &  26 & 2.21 & (0.90, 5.41) &  &  20 & 1.55 & (0.48, 4.95) &  & 1.58 & (0.48, 5.16) &  & 1.68 & (0.50, 5.64) \\ 
  \multicolumn{3}{l}{Synthetic}\\
 & $0$ &  66 &  &  &  &  41 &  &  &  &  &  &  &  &  \\ 
   & $>0$ to $0.7$  &  13 & 1.18 & (0.55, 2.50) &  &   7 & 0.77 & (0.31, 1.92) &  & 0.82 & (0.32, 2.09) &  & 0.77 & (0.31, 1.93) \\ 
   & $>0.7$ &  11 & 0.82 & (0.39, 1.72) &  &  10 & 0.84 & (0.36, 1.98) &  & 0.93 & (0.39, 2.22) &  & 0.84 & (0.35, 1.98) \\ 
   \bottomrule
\end{tabular}
\end{adjustbox}\end{table}


# 

## Non-Hodgkin lymphoma (exposure lagged 10 years)

\begin{table}\linespread{1.15}
\begin{adjustbox}{scale = 0.7}
%\caption{Adjusted HR estimates for non-hodgkin lymphoma.}
\begin{tabular}{llrlllrllllllll}
  \toprule & & \multicolumn{3}{c}{Full follow-up}& & \multicolumn{3}{c}{1985 cohort}& & \multicolumn{2}{c}{Weighted by surv.}& & \multicolumn{2}{c}{St. inverse weight}\\
\cline{3-5} \cline{7-9} \cline{11-12} \cline{14-15}
\vspace{0em} & \vspace{0em} & $n$ & HR & 95\% CI &   & $n$ & HR & 95\% CI &   & HR & 95\% CI &   & HR & 95\% CI \\ 
  \midrule
\multicolumn{3}{l}{Straight}\\
 & $0$ &  39 &  &  &  &  22 &  &  &  &  &  &  &  &  \\ 
   & $>0$ to $2$  &  30 & 0.83 & (0.45, 1.53) &  &  20 & 0.92 & (0.45, 1.90) &  & 0.93 & (0.44, 1.94) &  & 0.94 & (0.45, 1.94) \\ 
   & $>2$ &  21 & 1.15 & (0.66, 2.00) &  &  16 & 1.37 & (0.70, 2.68) &  & 1.41 & (0.72, 2.77) &  & 1.38 & (0.71, 2.71) \\ 
  \multicolumn{3}{l}{Soluble}\\
 & $0$ to $0.05$ &   9 &  &  &  &   4 &  &  &  &  &  &  &  &  \\ 
   & $>0.05$ to $5.1$  &  25 & 1.40 & (0.64, 3.07) &  &  19 & 1.61 & (0.54, 4.83) &  & 1.54 & (0.51, 4.66) &  & 1.85 & (0.59, 5.78) \\ 
   & $>5.1$ to $15.8$  &  27 & 1.66 & (0.71, 3.92) &  &  14 & 1.35 & (0.41, 4.50) &  & 1.37 & (0.41, 4.57) &  & 1.51 & (0.43, 5.28) \\ 
   & $>15.8$ &  29 & 1.87 & (0.80, 4.37) &  &  21 & 1.89 & (0.58, 6.22) &  & 1.93 & (0.59, 6.35) &  & 2.09 & (0.60, 7.26) \\ 
  \multicolumn{3}{l}{Synthetic}\\
 & $0$ &  63 &  &  &  &  38 &  &  &  &  &  &  &  &  \\ 
   & $>0$ to $1.2$  &  13 & 0.76 & (0.37, 1.55) &  &   9 & 0.72 & (0.31, 1.69) &  & 0.77 & (0.33, 1.82) &  & 0.73 & (0.31, 1.72) \\ 
   & $>1.2$ &  14 & 0.94 & (0.48, 1.81) &  &  11 & 1.10 & (0.50, 2.43) &  & 1.27 & (0.57, 2.82) &  & 1.10 & (0.49, 2.45) \\ 
   \bottomrule
\end{tabular}
\end{adjustbox}\end{table}


# 

## Non-Hodgkin lymphoma (exposure lagged 5 years)

\begin{table}\linespread{1.15}
\begin{adjustbox}{scale = 0.7}
%\caption{Adjusted HR estimates for non-hodgkin lymphoma.}
\begin{tabular}{llrlllrllllllll}
  \toprule & & \multicolumn{3}{c}{Full follow-up}& & \multicolumn{3}{c}{1985 cohort}& & \multicolumn{2}{c}{Weighted by surv.}& & \multicolumn{2}{c}{St. inverse weight}\\
\cline{3-5} \cline{7-9} \cline{11-12} \cline{14-15}
\vspace{0em} & \vspace{0em} & $n$ & HR & 95\% CI &   & $n$ & HR & 95\% CI &   & HR & 95\% CI &   & HR & 95\% CI \\ 
  \midrule
\multicolumn{3}{l}{Straight}\\
 & $0$ &  39 &  &  &  &  22 &  &  &  &  &  &  &  &  \\ 
   & $>0$ to $2$  &  29 & 0.75 & (0.42, 1.36) &  &  20 & 0.94 & (0.46, 1.89) &  & 0.94 & (0.46, 1.92) &  & 0.94 & (0.46, 1.91) \\ 
   & $>2$ &  22 & 1.07 & (0.63, 1.84) &  &  16 & 1.31 & (0.68, 2.54) &  & 1.34 & (0.69, 2.61) &  & 1.31 & (0.68, 2.55) \\ 
  \multicolumn{3}{l}{Soluble}\\
 & $0$ to $0.05$ &   7 &  &  &  &   4 &  &  &  &  &  &  &  &  \\ 
   & $>0.05$ to $5.1$  &  25 & 1.35 & (0.59, 3.14) &  &  18 & 1.43 & (0.48, 4.26) &  & 1.33 & (0.44, 4.00) &  & 1.41 & (0.47, 4.21) \\ 
   & $>5.1$ to $17.7$  &  28 & 1.47 & (0.61, 3.54) &  &  15 & 1.19 & (0.37, 3.90) &  & 1.20 & (0.37, 3.94) &  & 1.18 & (0.36, 3.84) \\ 
   & $>17.7$ &  30 & 1.98 & (0.83, 4.73) &  &  21 & 1.97 & (0.61, 6.42) &  & 1.98 & (0.61, 6.43) &  & 1.92 & (0.59, 6.23) \\ 
  \multicolumn{3}{l}{Synthetic}\\
 & $0$ &  63 &  &  &  &  38 &  &  &  &  &  &  &  &  \\ 
   & $>0$ to $1.2$  &  13 & 0.70 & (0.34, 1.41) &  &   9 & 0.68 & (0.29, 1.58) &  & 0.73 & (0.31, 1.69) &  & 0.67 & (0.28, 1.57) \\ 
   & $>1.2$ &  14 & 0.84 & (0.44, 1.59) &  &  11 & 1.01 & (0.47, 2.19) &  & 1.16 & (0.53, 2.51) &  & 1.01 & (0.46, 2.19) \\ 
   \bottomrule
\end{tabular}
\end{adjustbox}\end{table}

